" class="no-js "lang="en-US"> Covalab - Medtech Alert
Saturday, August 16, 2025
Covalab | Pharmtech Focus

Covalab

About Covalab

Covalab

Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995.

We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website.

The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the scientists at CovalAb have more than 30 years of experience in the chemical modification of antigens and antibodies destined for diagnosis and therapy.

A list, by no means complete of some of their achievements:
– In biomedicine, includes the production of: antibodies directed against new tumour markers, antibodies as gene vectors in cancerology, antibodies reacting specifically with cerebral protein aggregates in neurology, diagnostic kits for detecting patients with autoimmune disease such as rheumatoid arthritis and celiac disease.
– In agro-food, the development of complete diagnostic kits including the antibodies and the chemically modified immunogens for the detection of mycotoxins, phycotoxins, pesticides and polyaromatic hydrocarbons.

Our mission is to give to researchers every day high quality antibodies and powerful tools to accelerate your research and move on to discovery. We help our clients to face new challenges in biology and to improve life thanks to translational research, personalized medicine, stem cell therapy and food safety.

Related Story

Covalab, Cimcure and Partners Receive €1.06M EUREKA Eurostars Grant to Develop New Combination Therapy for Glioblastoma

September 21 2022

Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and […]

Covalab Invests More Than €1 Million in Bioproduction Operations for Antibodies for Covid-19 Diagnostics

May 23 2022

Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and […]

Oncodesign, Covalab, CheMatech and ABX-CRO Launch DRIVE™-MRT, a Premium Complete, Integrated Service Offer for Radiopharmaceuticals Drug Discovery and Generation

July 2 2021

ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing […]